Related references
Note: Only part of the references are listed.Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma
Oren J. Becher et al.
CANCER RESEARCH (2010)
Targeted Therapy for Malignant Glioma Patients: Lessons Learned and the Road Ahead
Tiffany T. Huang et al.
NEUROTHERAPEUTICS (2009)
Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations
Cameron Brennan et al.
PLOS ONE (2009)
Modeling Adult Gliomas Using RCAS/t-va Technology
Dolores Hambardzumyan et al.
TRANSLATIONAL ONCOLOGY (2009)
Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
[Anonymous]
NEOPLASIA (2009)
Combination therapy for malignant glioma based on PTEN status
Javier Gonzalez et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival
Daniel A. Hamstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma
John G. Kuhn et al.
CLINICAL CANCER RESEARCH (2007)
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial
Karen G. Chee et al.
CLINICAL GENITOURINARY CANCER (2007)
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma
Patrick McConville et al.
CLINICAL CANCER RESEARCH (2007)
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells
Takayuki Ikezoe et al.
LEUKEMIA RESEARCH (2007)
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma
Robert de W. Marsh et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2007)
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells
Lorena de la Pena et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome
Bradford A. Moffat et al.
NEOPLASIA (2006)
Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts
SR Vink et al.
CLINICAL CANCER RESEARCH (2006)
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
DT Teachey et al.
BLOOD (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Phase II study of perifosine in previously untreated patients with metastatic melanoma
DS Ernst et al.
INVESTIGATIONAL NEW DRUGS (2005)
Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis
C Fumarola et al.
CELL DEATH AND DIFFERENTIATION (2005)
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial
E Galanis et al.
INVESTIGATIONAL NEW DRUGS (2005)
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo
H Momota et al.
CANCER RESEARCH (2005)
Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells
R Avellino et al.
BLOOD (2005)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
mTOR promotes urvival and astrocytic characteristics induced by Pten/Akt signaling in glioblastoma
XY Hu et al.
NEOPLASIA (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
LY294002 and rapamycin co-operate to inhibit T-cell proliferation
EM Breslin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Restraining PI3K: mTOR signalling goes back to the membrane
LS Harrington et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
JF Gera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model
L Uhrbom et al.
NATURE MEDICINE (2004)
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
A Chakravarti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Unravelling the activation mechanisms of protein kinase B/Akt
MP Scheid et al.
FEBS LETTERS (2003)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
MS Neshat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice
K Podsypanina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Medical progress: Brain tumors
LM DeAngelis
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors
TL Chenevert et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
